



11 March 2020

Company Announcements Office
Australian Securities Exchange
Exchange Centre
20 Bridge Street
Sydney, NSW 2000

Dear Sir/Madam

CLARIFICATION OF ANNOUNCEMENT - ROYAL NORTH SHORE HOSPITAL NANABIS™ ADVANCED CANCER TRIAL RESULTS

Further to the announcement made by Medlab Clinical Limited (ASX: MDC) on 9 March 2020, Medlab wishes to confirm that the individual p-values of the 2 validated pain scoring systems were:

- Numerical Pain Rating Scales (NRS) : p-value 0.046
- Brief Pain Inventory (BPI) : p-value 0.04

Both scoring systems used are in line with the World Health Organisation Pain guidelines and are routinely used in Pain Management practices.

As per the original announcement, the total cohort had meaningful pain reduction, a specific patient subset being breast or prostate cancers with bone metastasis had an average of 40% improvement in pain scores from baseline.

For and behalf of the Board.

Dr Sean Hall
Managing Director

ISSUED FOR:	MEDLAB CLINICAL LTD (ASX: MDC) – www.medlab.co
FOR FURTHER	DR SEAN HALL, CEO, MEDLAB CLINICAL
INFORMATION:	TEL: +61 2 8203 9520, sean_hall@medlab.co

ABOUT MEDLAB – www.medlab.co

Medlab Clinical is an Australian based medical life science company, developing therapeutic pathways for diagnosed chronic diseases. It is advanced in developing therapies for pain management, depression and obesity as well as earning revenue from sale of nutritional products in Australia and the United States. In pain management Medlab is developing cannabis-based medicines. The Medlab developed nano-particle medicine delivery system, NanoCelle™, is being applied to its medicines, nutritional products and off-patent drugs like statins. Medlab has a growing patent portfolio.